Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270), Reports Q2 2024 Tentative Revenue of KRW 874.7B, Up 66.94% YoY

Posted on August 7, 2024July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270), Reports Q2 2024 Tentative Revenue of KRW 874.7B, Up 66.94% YoY

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-08-07

Disclosure Type: Tentative Sales Performance (Consolidated Financial Statements) (Fair Disclosure)

💡 3-Second Summary

Celltrion announced its tentative consolidated financial results for Q2 2024, reporting revenue of KRW 874.7B and operating profit of KRW 72.4B. While revenue rose 66.94% year-on-year, and operating profit jumped 369.57% quarter-on-quarter, operating profit declined 60.39% compared to the same period last year.

📊 1. [Key Disclosure Content & Major Financial Figures Summary]

  • Unit: Million KRW, % (Tentative consolidated financial results)
  • Revenue:
    • Q2 2024 (Quarterly): KRW 874,741 million (Up 18.69% QoQ, Up 66.94% YoY)
    • 1H 2024 Cumulative: KRW 1,611,722 million (Up 43.71% compared to 1H 2023)
  • Operating Profit:
    • Q2 2024 (Quarterly): KRW 72,488 million (Up 369.57% QoQ, Down 60.39% YoY)
    • 1H 2024 Cumulative: KRW 87,925 million (Down 75.94% compared to 1H 2023)
  • Income Before Income Taxes:
    • Q2 2024 (Quarterly): KRW 104,197 million (Up 429.51% QoQ, Down 45.07% YoY)
    • 1H 2024 Cumulative: KRW 123,875 million (Down 68.87% compared to 1H 2023)
  • Net Income:
    • Q2 2024 (Quarterly): KRW 78,452 million (Up 277.75% QoQ, Down 48.00% YoY)
    • 1H 2024 Cumulative: KRW 99,220 million (Down 68.80% compared to 1H 2023)
  • Net Income Attributable to Owners of the Parent:
    • Q2 2024 (Quarterly): KRW 78,012 million (Up 247.68% QoQ, Down 47.11% YoY)
    • 1H 2024 Cumulative: KRW 100,450 million (Down 67.88% compared to 1H 2023)
  • Fair Disclosure Information:
    • Provider / Target Audience: Celltrion IR Team / Domestic and International Investors, Media, etc.
    • Disclosure Date: August 7, 2024

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This regulatory filing is a fair disclosure officially presenting Celltrion’s tentative consolidated revenue and earnings performance for the second quarter and first half of fiscal year 2024.

From a financial perspective, Q2 2024 revenue reached KRW 874.7B, expanding 18.69% compared to the previous quarter (KRW 736.9B) and growing 66.94% compared to Q2 2023 (KRW 523.9B), demonstrating top-line expansion. Quarterly operating profit improved to KRW 72.4B, representing a 369.57% increase compared to Q1 2024 (KRW 15.4B). However, this figure declined 60.39% compared to Q2 2023 (KRW 182.9B), which also led to a 75.94% decrease in cumulative first-half operating profit (KRW 87.9B) compared to the first half of 2023 (KRW 365.4B). Other profitability indicators, such as income before income taxes and net income, showed a strong rebound quarter-on-quarter but experienced decreases of 40% to 50% year-on-year. Investors should evaluate both the quarter-on-quarter recovery and the year-on-year variance.

📝 Editor’s Comment (by K-STOCK Editor)

Applied Comment Style: Cautionary View

This tentative earnings disclosure is based on Celltrion’s internal settlement data prior to the completion of the external audit. Consequently, these figures remain subject to adjustments and revisions upon the finalization of the audit.

Investors analyzing this data must note that the filing provides only quantitative figures and percentage variances. The underlying operational and accounting drivers (such as selling, general, and administrative expenses, amortization of intangible assets, or fluctuations in cost of sales) that contributed to the simultaneous year-on-year revenue expansion and year-on-year operating profit decrease are not specified in this filing. Any qualitative conclusions regarding these financial drivers should not be drawn solely from this document.

Consequently, the objective checkpoints for investors to monitor going forward are twofold: first, whether the quantitative data in this tentative disclosure matches the finalized figures in the upcoming “H1 2024 Half-Year Report” down to the exact digit; and second, verifying the detailed cost allocations and expense items by cross-referencing the official IR materials published on Celltrion’s website to evaluate the underlying financial health. Monitoring these official financial publications remains the necessary pathway to verifying the company’s actual performance.

📢 Disclaimer & Source Information

Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

Bio & Healthcare, Disclosures

Post navigation

Previous Post: [Disclosure] Jeju Semiconductor (080220) Transitions to Single CEO Model Under Park Sung-sik Following Jo Hyung-sup’s Resignation
Next Post: [Disclosure] Hanwha Aerospace (012450) – Scheduled Market Measures Notice for Stock Futures/Options Due to Corporate Spin-off: Expiry Date Scheduled for Change to August 28, 2024 (Re-notice)

Related Posts

[Disclosure] Samsung Biologics (207940) Extends Nondisclosure Period for 2019 UCB CMO Contract Until Year-End 2031 Disclosures
[Disclosure] Jusung Engineering (036930) Amends Corporate Split Report: Confirms ‘Spin-off (Demerger)’ of Semiconductor Unit and Recalculates Capital Following Treasury Stock Burn Semiconductors
[Disclosure] Isu Petasys (007660) Scraps KRW 42.0B Jeio Convertible Bond Deal; Total M&A Terminated Due to Seller’s Breach of Contract Semiconductors
[Disclosure] HPSP(403870) Schedules EGM for Sept 5; Set to Vote on 1.5-Year Term Extension for Incumbent CEO Yong-woon Kim Semiconductors
[Disclosure] Hanwha Aerospace (012450) – Clarification on Rumors or News Reports (Unconfirmed Notice Regarding Equity Demerger Reports) Disclosures
[Title] [Disclosure] HANMI Semiconductor (042700) Completes Retirement of 379,375 Shares – Relisting Announcement Scheduled for Nov 28 to Boost Shareholder Value Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme